Workup of Mild Thrombocytosis in a 70-Year-Old with Hypertension
In a 70-year-old patient with mild thrombocytosis and hypertension, first exclude secondary causes (malignancy, inflammation, iron deficiency, splenectomy) through targeted clinical assessment and basic labs, then proceed to JAK2/CALR/MPL mutation testing if secondary causes are ruled out, as this patient's age >60 years places them at high risk for thrombotic complications if essential thrombocythemia (ET) is present. 1
Initial Clinical Assessment
Identify Secondary Causes First
The most common secondary causes that must be excluded include: 2
- Active malignancy - strongly associated with reactive thrombocytosis 2
- Chronic inflammatory disease (connective tissue disease, infection) - key predictor of secondary thrombocytosis 2
- Iron deficiency anemia - common cause of reactive thrombocytosis 3, 2
- Prior splenectomy - definitive cause of secondary thrombocytosis 3, 2
- Recent surgery or trauma 3
Hypertension Connection
Important caveat: Essential thrombocythemia can actually cause hypertension through renal artery stenosis and renal microvascular lesions. 4, 5 In young patients with ET and hypertension, renal artery thrombosis should be considered, though this is less common in older patients. 5
Laboratory Workup Algorithm
Step 1: Basic Laboratory Tests
Complete blood count with differential - assess hemoglobin, MCV, RDW, MPV, and white blood cell count 2
Inflammatory markers (CRP, ESR) - if chronic inflammatory disease suspected 2
Step 2: Bone Marrow Biopsy (If Pursuing ET Diagnosis)
Required to confirm ET diagnosis, showing: 3
- Proliferation mainly of megakaryocytic lineage with increased numbers of enlarged, mature megakaryocytes 3
- Large, mature-appearing megakaryocytes with deeply lobulated and hyperlobulated nuclei 3
- No significant increase or left-shift of neutrophil granulopoiesis or erythropoiesis 3
- Absence of relevant reticulin or collagen fibrosis 3
Step 3: Molecular Testing (If Secondary Causes Excluded)
Proceed with JAK2/CALR/MPL mutation testing if clinical and laboratory features suggest primary thrombocytosis: 3, 2
- JAK2V617F mutation testing has highest yield (92.1% of positive molecular tests in ET are JAK2, CALR, or MPL) 2
- Overall yield of molecular testing in thrombocytosis is 52.4% 2
- Presence of clonal marker (JAK2V617F or other) is required for ET diagnosis in absence of other WHO criteria 3
WHO Diagnostic Criteria for Essential Thrombocythemia
All four criteria must be met: 3
- Sustained platelet count ≥450 × 10⁹/L 3
- Bone marrow biopsy showing characteristic findings (as above) 3
- Exclusion of other myeloid neoplasms (PV, PMF, CML, MDS) 3
- Demonstration of JAK2V617F or other clonal marker, OR in absence of clonal marker, no evidence for reactive thrombocytosis 3
Risk Stratification Critical for This Patient
This 70-year-old patient is automatically HIGH-RISK due to age >60 years, regardless of thrombosis history. 1
Key Risk Factors for Thrombosis:
- Age >60 years - most consistent risk factor (this patient qualifies) 1
- Prior thrombosis history - assess carefully 1
- JAK2 mutation status - if positive, increases thrombotic risk 1
Important Nuance on Platelet Count:
**Mild thrombocytosis (<1,000 × 10⁹/L) does NOT require immediate cytoreductive therapy based on platelet count alone.** 1 In fact, very high platelet counts (>1,000 × 10⁹/L) are associated with bleeding risk but paradoxically lower thrombosis rates. 1
Clinical Pitfalls to Avoid
- Do not order expensive molecular testing before excluding obvious secondary causes - this reduces unnecessary investigation and costs 2
- Do not assume hypertension is unrelated - ET can cause renovascular hypertension, though rare 4, 5
- Do not rely on platelet count severity alone - mild thrombocytosis can still represent ET requiring treatment in high-risk patients 1
- Do not forget to assess for arterial thrombosis history - this is predictive of ET diagnosis 2